Curetis To Attend Key Conferences in the Third Quarter of 2019
02 Juillet 2019 - 8:00AM
Amsterdam, the Netherlands, and
Holzgerlingen, Germany, July 2, 2019, 08:00 am CET -
Curetis N.V. (the "Company" and, together with its
subsidiaries, "Curetis"), a developer of next-level molecular
diagnostic solutions, today announced that the Company will be
attending several key conferences in the third quarter of 2019.
August 2019 European Biotech Investor Day 2019 by
Goodwin, Solebury Trout, August 1, 2019 – New York, NY,
USA – Company presentation and 1-on-1 investor meetings.
71st AACC Annual Scientific Meeting & Clinical Lab
Expo, August 4-8, 2019 – Anaheim, CA, USA – Visit Curetis
at booth #3611.
September 2019:
Southwestern Association for Clinical
Microbiology (SWACM), September 4-7 – Oklahoma City, OK,
USA – Meet Curetis’ U.S. sales team to learn more about the Unyvero
LRT panel providing clear directions for the treatment of
hospitalized pneumonia patients.
H.C. Wainwright Global Life Sciences
Conference, September 8-9, 2019 – Lotte New York Palace
Hotel, New York, NY, USA – Company presentation and 1-on-1 investor
meetings.
Baader Investment Conference – Baader
Small-Cap Day, September 27, 2019 – Hotel Sofitel Munich
Bayerpost, Munich, Germany – Company presentation and 1-on-1
investor meetings.
###
About Curetis
Curetis N.V.’s (Euronext: CURE) goal is to
become a leading provider of innovative solutions for molecular
microbiology diagnostics designed to address the global challenge
of detecting severe infectious diseases and identifying antibiotic
resistances in hospitalized patients.
Curetis’ Unyvero System is a versatile, fast and
highly automated molecular diagnostic platform for easy-to-use,
cartridge-based solutions for the comprehensive and rapid detection
of pathogens and antimicrobial resistance markers in a range of
severe infectious disease indications. Results are available within
hours, a process that can take days or even weeks if performed with
standard diagnostic procedures, thereby facilitating improved
patient outcomes, stringent antibiotic stewardship and
health-economic benefits. Unyvero in vitro diagnostic (IVD)
products are marketed in Europe, the Middle East, Asia and the
U.S.
Curetis’ wholly owned subsidiary Ares Genetics
GmbH is developing next-generation solutions for infectious disease
diagnostics and therapeutics. The ARES Technology Platform combines
the presumably most comprehensive database worldwide on the
genetics of antimicrobial resistances, ARESdb, with advanced
bioinformatics and artificial intelligence.
For further information, please visit
www.curetis.com and www.ares-genetics.com.
Legal Disclaimer
This document constitutes neither an offer to
buy nor to subscribe securities and neither this document nor any
part of it should form the basis of any investment decision in
Curetis.
The information contained in this press release
has been carefully prepared. However, Curetis bears and assumes no
liability of whatever kind for the correctness and completeness of
the information provided herein. Curetis does not assume an
obligation of whatever kind to update or correct information
contained in this press release whether as a result of new
information, future events or for other reasons.
This press release includes statements that are,
or may be deemed to be, “forward-looking statements”. These
forward-looking statements can be identified by the use of
forward-looking terminology, including the terms “believes”,
“estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, or
“should”, and include statements Curetis makes concerning the
intended results of its strategy. By their nature, forward-looking
statements involve risks and uncertainties and readers are
cautioned that any such forward-looking statements are not
guarantees of future performance. Curetis’ actual results may
differ materially from those predicted by the forward-looking
statements. Curetis undertakes no obligation to publicly update or
revise forward-looking statements, except as may be required by
law.
Contact Details
Curetis GmbHMax-Eyth-Str.
4271088 Holzgerlingen, GermanyTel. +49 7031 49195-10pr@curetis.com
or ir@curetis.comwww.curetis.com
Curetis International Media &
Investor InquiriesakampionDr. Ludger Wess / Ines-Regina
Buth Managing Partnersinfo@akampion.comTel. +49 40 88 16 59 64Tel.
+49 30 23 63 27 68
- 20190702_PR_Conferences_Q3_2019_final_approved
Direxion Daily Healthcar... (AMEX:CURE)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Direxion Daily Healthcar... (AMEX:CURE)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025